TWO INJECTABLE STENTS – ONE INCREDIBLE GAME-CHANGER

With two stents preloaded in a single-use injector, iStent inject W represents the next generation
of trabecular micro-bypass technology for patients with glaucoma, and is designed to:

• Optimize natural outflow
• Significantly reduce IOP
• Provide the predictability and precision to meet the needs of your practice
• Prioritize patient safety

iStent inject W creates two patent bypass pathways through the trabecular meshwork – the main source of resistance for aqueous outflow – resulting in multi-directional flow through Schlemm’s canal. And it is one of the smallest medical devices known to be implanted in the human body. Together, these unique advantages are designed to provide exceptional results in a truly micro-invasive approach

With iStent inject W, two multi-directional stents are placed two to three clock hours apart. Together, they are designed to deliver access to multiple collector channels and arcs of flow that can span five to six clock hours. iStent inject W may also re-establish flow in previously dormant outflow channels. (2)

Prioritize Safety and Outcomes

Putting the primary emphasis on maximizing benefits and minimizing long-term complications, iStent inject W is designed to support optimal outcomes after cataract surgery, and much more.

• Micro-invasive and astigmatically-neutral
• Utilizes the conventional outflow pathway
• Leaves natural anatomy intact, preserving the potential for future treatment options, including drug delivery devices
• Minimally traumatic to delicate eye tissue and spares conjunctival tissue
• Reduces the risk of hypotony by utilizing the natural episcleral venous pressure
• Offers postoperative care profile similar to cataract surgery

Working Principle

EXCEPTIONAL ELEGANCE – ADVANCED INNOVATION.

The iStent inject W System is engineered to provide an enhanced surgical experience and ensure confident delivery, for every procedure. With next-generation stent design, featuring a wide flange at its base, iStent inject W is designed to optimize stent visualization and placement, deliver procedural predictability and increase peace of mind.

REFERENCES:

1. Samuelson TW, Sarkisian SR, Lubeck DM, et al. Prospective, randomized, controlled pivotal trial of an ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract. Ophthalmology. Jun 2019;126(6):811-821.
2. Hengerer FH, Auffarth GU, Riffel C, Conrad-Hengerer I. Prospective, non-randomized, 36-month study of second-generation trabecular micro-bypass stents with phacoemulsification in eyes with various types of glaucoma. Ophthalmol Ther. 2018 Dec;7(2):405-415.